Angiogenesis 2022 – Regeneron and Bayer see positive signs for long-acting Eylea
The omens look good for the upcoming Pulsar readout, but can Eylea keep its wet AMD stranglehold?
Biggest unpartnered assets: Argenx nears crunch time
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Clearside’s long-acting eye project shows promise
But data are early, and other groups are also developing less frequent injections for wet AMD.
Some of biopharma’s biggest assets face a solo existence
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Few clues to flotation fever in past performance
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Safety scare knocks Novartis
Heightened Beovu safety concerns could turn into a big problem for Novartis, while rival Regeneron will make the most of any uncertainty.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.